An Analysis for Therapeutic Doses of Patients with Neuroendocrine Tumor Treated with Lutetium 177 (177Lu)-DOTATATE
| Autor: | Zeynep Gözde Özkan, Duygu Tunçman, Yasemin Sanli, Cuneyt Turkmen, Bayram Demir, Duygu Has Simsek, Bilal Kovan, Emine Goknur Isik, Fikret Büyükkaya |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
0301 basic medicine
Cancer Research medicine.medical_specialty medicine.medical_treatment Urology Neuroendocrine tumors 03 medical and health sciences 0302 clinical medicine Medicine Dosimetry Radiology Nuclear Medicine and imaging Pharmacology Diminution Kidney business.industry General Medicine medicine.disease Radiation therapy 030104 developmental biology medicine.anatomical_structure Oncology Bone marrow suppression 030220 oncology & carcinogenesis Radionuclide therapy Bone marrow business |
| Zdroj: | Cancer Biotherapy and Radiopharmaceuticals. 37:17-22 |
| ISSN: | 1557-8852 1084-9785 |
| DOI: | 10.1089/cbr.2021.0071 |
| Popis: | Background: The aim of this study is to clarify the critical organs that limit treatment scheme and also evaluate the validity of currently used critical organ threshold values in neuroendocrine tumor (NET) patients, receiving peptide receptor radionuclide therapy (PRRT) with Lutetium-177 (177Lu)-DOTATATE. Thirty-six NET patients (ages 16-73 years) who received 177Lu-DOTATATE treatment were evaluated retrospectively in this study. Dosimetric calculations were made using medical internal radionuclide dose method. For calculation of organ doses, Internal Dose Assessment at Organ Level/Exponential Modelling 1.1 software program was used. Follow-up data were used to determine the organ failure. Results: A total of 141 cycles and mean of 3.91 (±1.33) cycles were applied to the patients. A mean of 691 mCi (±257 mCi) 177Lu-DOTATATE infusion in total and a dose between 70 and 200 mCi per treatment was applied to patients. Seven of 36 patients reached 23 Gy renal dose limit. In these patients, although kidney doses were between 23 and 29 Gy, there was no diminution in renal functions during follow-up. Two of 36 patients reached total bone marrow dose of 2 Gy limit. Bone marrow suppression did not develop in these patients. Conclusion: The critical organs that seem to affect the treatment scheme in PRRT with 177Lu-DOTATATE are kidney and bone marrow. Although there are established threshold levels, derived from radiotherapy experience, more studies are needed to clarify these dose limits in systemic radionuclide therapies such as PRRT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|